This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated Sep 2026 quarter revenue up 23.5%, profit turns positive
NEPHROPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts less than Nifty Microcap 250 and 2.0 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
On a consolidated basis, revenue for the quarter ended September 30, 2026 rose 23.5% year on year to INR 3,033.98 million (September 2025: INR 2,457.18 million), while profit after tax was INR 335.31 million versus a loss of INR 94.74 million. The margin before interest, tax, depreciation and other income fell to 22.1% from 26.0%. Consolidated half-year operating cash flow was INR 894.39 million. The limited review conclusion was unmodified.
Revenue growth and a return to profit support sentiment, but a lower operating margin and higher short-term borrowings could limit the stock's upside.
| Q2 FY27 | Year ago | Change | |
|---|---|---|---|
| Revenue | ₹303.4 Cr | — | — |
| Operating profit | ₹36.33 Cr | — | — |
| Profit after tax | ₹33.53 Cr | — | — |
| EBITDA margin | 22.1% | — | — |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income. No year-ago figures on this basis yet, so no comparison.